Scientific substantiation of the concept of pharmacoeconomic analysis of technologies for early diagnosis and pharmacotherapy of pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by high blood pressure (hypertension) in the arteries of the lungs (pulmonary artery) for no apparent reason.
Because symptoms are nonspecific and physical signs may be subtle, the disease is often diagnosed at late stages. Over the past few decades, significant progress has been made in the field of pulmonary arterial hypertension. Technological progress allows to diagnose the disease in the early stages, as well as to better assess the severity of the disease.
Today, screening studies are becoming increasingly important to establish a clinical diagnosis and minimize lost opportunities without timely diagnosis, especially in patients with idiopathic PAH.
Therefore, the issue of early diagnosis of patients with suspected PAH and confirmation of the diagnosis is a very important and urgent issue today.
The objective of the paper: to study the methods of implementation of technologies for early diagnosis and pharmacotherapy of pulmonary arterial hypertension and conceptual presentation of the results of their implementation.
The work used available scientific sources of information on the results of the implementation of diagnostic screening for early detection of PAH and pharmacotherapy in the world. The analysis of input data was carried out using systematic, documentary, informational and graphical research methods.
The result of the analysis of information materials showed that over the past two decades, significant progress has been made in the treatment of PAH and more than doubled the survival rate of patients.
It has been found that diagnostic screening is a relatively unique medical technology in relation to other medical interventions and can be defined as the systematic use of diagnostic technologies in individuals at risk to detect the disease before the onset of symptoms.
The study proposes a systematic concept of economic evaluation of the diagnostic screening program for PAH to determine its optimal design.
At the same time, this concept embodies the complex effect of the introduction of technologies for early diagnosis and pharmacotherapy of PAH, which is expressed in the positive dynamics of clinical indicators, reduced mortality and improved quality of life.
It should be noted that a number of new tools and approaches for diagnostic screening give hope that advances in the diagnosis of PAH will also affect the effectiveness of medical care.
Konstantinides S. V., Meyer G., Becattini C. et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) // Eur. Respir. J. – 2019. – N 54. https://doi.org/10.1183/13993003.01647-2019
Ende-Verhaar Y. M., Huisman M. V., Klok F. A. To screen or not to screen for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism // Thromb. Res. – 2017. – N 151. – P. 1–7. https://doi.org/10.1016/j.thromres.2016.12.026
Boon G. J. A. M., Bogaard H. J., Klok F. A. Essential aspects of the follow-up after acute pulmonary embolism: an illustrated review // Res. Pract. Thromb. Haemost. – 2020. – N 4. – P. 958–968. https://doi.org/10.1002/rth2.12404
Boon G. J. A. M., Ende-Verhaar Y. M., Bavalia R. et al. Non-invasive early exclusion of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: the InShape II study // Thorax. – 2021. – N 76. – P. 1002–1009. https://doi.org/10.1136/thoraxjnl-2020-216324
Ende-Verhaar Y. M., Ruigrok D., Bogaard H. J. et al. Sensitivity of a simple noninvasive screening algorithm for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism // Thieme. – 2018. – N 2. – P. 89–95. https://doi.org/110.1055/s-0038-1636537
Ende-Verhaar Y. M., van den Hout W. B., Bogaard H. J. et al. Healthcare utilization in chronic thromboembolic pulmonary hypertension after acute pulmonary embolism // J. Thromb. Haemost. – 2018. – N 16. – P. 2168–2174. https://doi.org/10.1111/jth.14266
Klok F. A., Barco S., Konstantinides S. V. et al. Determinants of diagnostic delay in chronic thromboembolic pulmonary hypertension: results from the European CTEPH Registry // Eur. Respir. J. – 2018. – N 52. https://doi.org/10.1183/13993003.01687-2018
Brown L. M., Chen H., Halpern S. et al. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry // Chest. – 2011. – N 140. – P. 19–26. https://doi.org/10.1378/chest.10-1166
Humbert M., Yaici A., de Groote P. et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival // Arthritis Rheum. – 2011. – N 63. – P. 3522–3530. https://doi.org/10.1002/art.30541
Behr J., Nathan S. D. Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment // Current Opinion in Pulmonary Med. – 2021. – N 27. – P. 396–404. https://doi.org/10.1097/MCP.0000000000000790
Coquoz N., Weilenmann D., Stolz D. et al. Multicentre observational screening survey for the detection of CTEPH following pulmonary embolism // Eur. Respir. J. – 2018. – N 51. https://doi.org/10.1183/13993003.02505-2017
Boon G. J. A. M., Huisman M. V., Klok F. A. Why, whom, and how to screen for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism // Semin. Thromb. Hemost. – 2021. – N 47. – P. 692–701. https://doi.org/10.1055/s-0040-1718925
DU «Derzhavnyi ekspertnyi tsentr MOZ Ukrainy». Adaptovana klinichna nastanova [Elektronnyi resurs]. – Rezhym dostupu: dec.gov.ua/wp-content/uploads/2019/11/2016_614_akn_leggipert.pdf
Wong W. W., Hong- Ahn T., Feld J. et al. Cost-effectiveness of screening for hepatitis C in Canada // CMAJ. – 2015. – N 187. – P. 110–121. https://doi.org/10.1503/cmaj.140711
Aronsson M., Svennberg E., Rosenqvist M. et al. Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording // Europace. – 2015. – N 17. – P. 1023–1029. https://doi.org/10.1093/europace/euv083
Alarid F., Enns E., Kuntz K. et al. «Time Traveling Is Just Too Dangerous» but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier // Value in Health. – 2019. – N 22. – P. 611–618. https://doi.org/10.1016/j.jval.2019.02.008
Akizuki A., Sugimura K., Aoki T. et al. Non-invasive screening using ventilatory gas analysis to distinguish between chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension // Wiley online library. – 2019. – N 25. – P. 343–457. https://doi.org/10.1111/resp.13618
This work is licensed under a Creative Commons Attribution 4.0 International License.